ImmuCell Corporation (ICCC) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
ImmuCell (ICCC) Q4 2025: TriShield Up 41% as First Defense Refocus Drives Strategic Reset
June 15, 2026
-
Immucell (ICCC) Q1 2026: Tri-Shield Drives 38% Growth, Capturing 80% of Market Expansion
May 15, 2026
-
EmuCell (ICCC) Q3 2025: Gross Margin Soars to 43% as Supply Constraints Ease
November 14, 2025
-
ICCC Q2 2025: Gross Margin Doubles to 44% as Backlog Clears, Setting Up Competitive Reset
August 15, 2025